Literature DB >> 17186990

Reverse perfusion-metabolism mismatch predicts good prognosis in patients undergoing cardiac resynchronization therapy: a pilot study.

Noriko Inoue1, Nobukazu Takahashi, Toshiyuki Ishikawa, Shinichi Sumita, Tsukasa Kobayashi, Kohei Matsushita, Katsumi Matsumoto, Minoru Taima, Miei Shimura, Kazuaki Uchino, Kazuo Kimura, Tomio Inoue, Satoshi Umemura.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) improves glucose metabolism in the septum of patients with heart failure, so in the present study the predictive value of combined fluorodeoxyglucose (FDG)-positron emission tomography (PET) and metoxy-isobutyl isonitrile (MIBI)-single photon emission computed tomography (SPECT) for the prognosis of patients undergoing CRT was investigated. METHODS AND
RESULTS: Fourteen patients (70.3+/-8.2 years) who underwent FDG-PET and MIBI-SPECT before implantation of a biventricular pacemaker were enrolled. The total number of matches, mismatches, reverse mismatches, summed difference score (SDS: sum total of FDG - MIBI scores) and SDS per segment (%SDS) in each of 5 areas of myocardium (septum, anterior, lateral, inferior area, apex) was calculated and compared between the survival groups (all survival: survival group; survival without ischemic heart disease (IHD): non-IHD survival group) and non-survival group. Both the number of reverse mismatch segments and the %SDS in the septum in the non-IHD survival group were significantly greater than in the non-survival group (3.2+/-1.6 vs 0.5+/-0.6, p<0.05; 0.62+/-0.61 vs -0.11+/-0.19, p<0.05). The receiver-operating characteristics curves for prognosis showed that the area under the curve for the number of reverse mismatch segments in the septum (0.93; confidence interval 0.61-0.98) was significantly greater.
CONCLUSION: A reverse mismatch pattern in the septum can predict a good prognosis for patients treated with CRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186990     DOI: 10.1253/circj.71.126

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy.

Authors:  David Birnie; Rob A de Kemp; Anthony S Tang; Terence D Ruddy; Michael H Gollob; Ann Guo; Kathryn Williams; Kerry Thomson; Jean N DaSilva; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2011-12-10       Impact factor: 5.952

Review 2.  Cardiovascular molecular imaging: focus on clinical translation.

Authors:  Ian Y Chen; Joseph C Wu
Journal:  Circulation       Date:  2011-02-01       Impact factor: 29.690

3.  Altered myocardial glucose utilization and the reverse mismatch pattern on rubidium-82 perfusion/F-18-FDG PET during the sub-acute phase following reperfusion of acute anterior myocardial infarction.

Authors:  Daniel D Anselm; Anjali H Anselm; Jennifer Renaud; Harold L Atkins; Robert de Kemp; Ian G Burwash; Kathryn A Williams; Ann Guo; Cathy Kelly; Jean Dasilva; Rob S B Beanlands; Christopher A Glover
Journal:  J Nucl Cardiol       Date:  2011-05-13       Impact factor: 5.952

Review 4.  The Modulating Effects of Cardiac Resynchronization Therapy on Myocardial Metabolism in Heart Failure.

Authors:  Yi-Zhou Xu; Chao-Feng Chen; Bin Chen; Xiao-Fei Gao; Wei Hua; Yong-Mei Cha; Petras P Dzeja
Journal:  Pacing Clin Electrophysiol       Date:  2016-12-07       Impact factor: 1.976

5.  Radionuclide Imaging of Viable Myocardium: Is it Underutilized?

Authors:  Ilias Mylonas; Rob S B Beanlands
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-19

Review 6.  New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease.

Authors:  Oyebola O Sogbein; Matthieu Pelletier-Galarneau; Thomas H Schindler; Lihui Wei; R Glenn Wells; Terrence D Ruddy
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.